trending Market Intelligence /marketintelligence/en/news-insights/trending/9y7zgmhplq7tuyssafmxgq2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

TiGenix, Takeda's stem cell therapy gets European approval

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


TiGenix, Takeda's stem cell therapy gets European approval

TiGenix NV and Takeda Pharmaceutical Co. Ltd. received European Commission approval for Alofisel to treat conditions associated with Crohn's disease — an inflammatory bowel disease that affects the lining of the digestive tract.

The marketing authorization would allow Alofisel, or darvadstrocel, to treat complex perianal fistulas, or tunnels caused by ulcers around the anus, in adult patients with nonactive/mildly active luminal Crohn's disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy.

Alofisel is the first allogeneic stem cell therapy to receive central marketing authorization approval in Europe.

The drug received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use in December 2017.

Takeda agreed to buy Belgium-based TiGenix in January for about €520 million in cash, subject to certain conditions including the receipt of European marketing authorization for Alofisel.

Earlier, Belgium-based TiGenix had licensed Alofisel to Takeda for its exclusive development and commercialization outside the U.S.

The European approval will trigger a €15 million milestone payment from Takeda to TiGenix, along with the transfer of marketing application to the Japanese drugmaker.

Takeda's tender offer for TiGenix will also be subject to other conditions, including tendering of TiGenix securities representing 85% or more of its voting rights.